Renaissance Capital logo

CHRS News

US IPO Weekly Recap: 8 companies go public with strong returns as 5 delay IPOs

This week saw 8 IPOs raise $1.7 billion. While 5 of the 13 were delayed, the rest averaged 18% return, and all but one ended the week positive. Broader markets continue to rally as the Dow and S&P 500 closed at new record highs and the VIX volatility index slid another 6%. Despite these trends, IPO investors remain discerning: in addition to the postponed offerings, this week's...read more

Coherus BioSciences prices IPO at $13.50 midpoint

Coherus BioSciences, a clinical-stage biologics platform company focused on the emerging biosimilars market, raised $85 million by offering 6.3 million shares at $13.50, the midpoint of the range of $12 to $15. Insiders planned to buy $35 million on the IPO. Coherus BioSciences plans to list on the NASDAQ under the symbol CHRS. Coherus BioSciences initially filed confidentially on...read more

Week Ahead: 12 US IPOs planned for the week of November 3 as the IPO market reignites

AM

12 US IPOs are expected to raise $1.7 billion this week. Following three weeks with 5 or fewer initial public offerings, the IPO calendar has quickly built up thanks to a rebound in the broader markets, positive IPO performance and a packed pipeline of deals on file. While the IPO window...read more

Enbrel biosimilar biotech Coherus BioSciences sets terms for $85 million IPO

Coherus BioSciences, which is developing a biosimilar version of Amgen's Enbrel treatment for inflammatory diseases, announced terms for its IPO on Friday. The Redwood City, CA-based company plans to raise $85 million by offering 6.3 million shares at a price range of $12 to $15. At the midpoint of the proposed range, it would command a fully diluted market value of $508 million. ...read more